MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
INmune Bio DSO Ratio 2011-2026 | INMB
Annual DSO Ratio INmune Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.9 K | 15.4 K | - | - | - | 60.1 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 60.1 K | 15.4 K | 31.8 K |
Quarterly DSO Ratio INmune Bio
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.25 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.25 K | 2.25 K | 2.25 K |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 46.5 | -4.52 % | $ 12.6 B | USA |
 |
Fortress Biotech
FBIO
|
115 | $ 2.47 | -3.18 % | $ 68.9 M | USA |
 |
Heron Therapeutics
HRTX
|
198 | $ 1.24 | -5.73 % | $ 207 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
20.5 | $ 76.1 | -0.98 % | $ 12.2 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 212.22 | -8.74 % | $ 3.88 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.18 | 3.26 % | $ 3.68 B | USA |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 42.07 | -0.17 % | $ 3.62 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.15 | - | $ 655 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 101.66 | -7.65 % | $ 5.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.63 | 8.36 % | $ 5.98 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
MannKind Corporation
MNKD
|
26.2 | $ 3.65 | 2.39 % | $ 1.12 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Genmab A/S
GMAB
|
97.9 | $ 27.58 | -1.11 % | $ 17 B |  Danmark |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 22.31 | -7.72 % | $ 2.84 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |